

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

Claims 1-40 (Cancelled).

41. (Currently Amended) A method of preparing dual specificity T lymphocytes comprising:

(i) contacting T lymphocytes in a ~~mixed~~ population of ~~cells~~ T lymphocytes *ex vivo* with a cell that is allogeneic to one or more T lymphocytes wherein the allogeneic cell is selected from the group consisting of dendritic cells, B lymphocytes and peripheral blood mononuclear cells (PBMCs), wherein contacting T lymphocytes with the allogeneic cell selects and specifically amplifies, from the ~~mixed~~ population of ~~cells~~ T lymphocytes, T lymphocytes comprising an ~~endogenous~~ a T cell receptor that is reactive with the allogeneic cell; and

(ii) transducing the T lymphocytes comprising the ~~endogenous~~ T cell receptor reactive with the allogeneic cell with a chimeric receptor gene, said gene encoding a ~~chimeric~~ fusion receptor between a single chain antibody that recognizes a tumor antigen and a T cell receptor capable of triggering T cell receptor signal transduction, which is reactive with a tumor antigen, to produce dual specificity T lymphocytes, wherein the dual specificity T lymphocytes generate an anti-tumor immune response *in vivo*.

Claims 42-93 (Cancelled).

94. (Currently Amended) The method of claim 41 comprising transducing the T lymphocytes comprising the ~~endogenous~~ T cell receptor reactive with the allogeneic cell with a retroviral vector comprising the chimeric receptor gene.

95. (Previously Presented) The method of claim 94, wherein the chimeric receptor comprises a single chain Fv receptor.

96. (Previously Presented) The method of claim 95, wherein the chimeric receptor is Mov-γ.

97. (Previously Presented) The method of claim 41, wherein the tumor antigen is an ovarian tumor antigen.

98. (Previously Presented) The method of claim 97, wherein the ovarian tumor antigen is folate binding protein (FBP).

Claim 99 (Cancelled).

100. (Currently Amended) The method of claim ~~99~~41, wherein the dual specificity T lymphocytes are human T lymphocytes.

101. (Previously Presented) The method of claim 100, wherein the human T lymphocytes are lymphocytes isolated from a human.

102. (Previously Presented) The method of claim 101, wherein the human comprises an ovarian cancer, melanoma, or colon cancer.

Claim 103 (Cancelled).

104. (Currently Amended) The method of claim ~~103~~41, comprising co-culturing the lymphocytes with allogeneic cells at a allogeneic cell:lymphocyte ratio that is about 2:1 to about 5:1.

105. (Previously Presented) The method of claim 41 further comprising contacting the lymphocytes with the cell that is allogeneic to the lymphocytes after transducing the lymphocytes with a chimeric receptor gene.

106. (Previously Presented) The method of claim 41, further comprising expanding the dual specificity lymphocytes in IL-2 containing media.

107. (Previously Presented) The method of claim 41, further comprising expanding the dual specificity lymphocytes by a Rapid Expansion Protocol (REP) comprising co-culturing the dual specificity lymphocytes with allogeneic PBMC in culture medium comprising OKT-3 and IL-2.

108. (Previously Presented) A composition comprising a population of cells comprising the lymphocytes prepared by the method of claim 41 and the cell that is allogeneic to the lymphocytes.

109. (Previously Presented) The composition of claim 108, wherein the population of cells consists essentially of the dual specificity lymphocytes and the allogeneic cell.

110. (Previously Presented) The method of claim 41, wherein selecting the lymphocytes includes pre-selecting the lymphocytes from a mixed population of cells and transducing the lymphocytes includes transducing pre-selected lymphocytes.

111. (Previously Presented) The composition of claim 108, wherein the lymphocytes are pre-selected from a mixed population of cells and transduced with the chimeric receptor gene.